Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.
about
HIV-Associated Pneumocystis PneumoniaPneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future DirectionsEpidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literatureEchinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infectionRestriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jirovecii isolates.Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: an observational cohort study.Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China.Ploidy of cell-sorted trophic and cystic forms of Pneumocystis carinii.Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina.The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.Pathological and protective immunity to Pneumocystis infection.Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from Pneumocystis jirovecii pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort.Pneumocystis S-adenosylmethionine transport: a potential drug target.The state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection.Use of Oropharyngeal Washes to Diagnose and Genotype Pneumocystis jirovecii.Colonization by Pneumocystis jirovecii and its role in disease.Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis.Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients.Environmental risk factors for Pneumocystis pneumonia hospitalizations in HIV patientsClinical and translational research in pneumocystis and pneumocystis pneumonia.Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.Current understanding of Pneumocystis immunology.Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort studyGood outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.Multilocus microsatellite genotyping array for investigation of genetic epidemiology of Pneumocystis jirovecii.Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia.Pneumocystis jirovecii multilocus gene sequencing: findings and implications.Update on the diagnosis and treatment of Pneumocystis pneumonia.Immune Modulation as Adjunctive Therapy for Pneumocystis pneumonia.Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.Recent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adults.
P2860
Q22241388-963D1664-7D9A-4EB8-AB03-12EC02C5090FQ26795592-336AB840-5D5E-4440-99F9-B44364CD9177Q28082149-111FCB1E-231E-400C-AEB7-E80296315E0CQ28472713-C58BC73E-0322-43D1-99A8-C7FEA448525AQ33579470-B88441F5-1FFB-42E7-94E2-BE8A61117CACQ33592578-9FC125B2-F0D0-4C94-B2FD-C44909CA6687Q33688400-9EBA919D-1B8F-48B7-A879-340369972F7AQ33707383-451CD94C-3F7E-4042-86BA-45554E0865F3Q33769075-423B3446-F6CC-4A84-8A4D-9280BD5D10FDQ33910458-188453A7-A901-4D3C-B449-0DF9A68DF374Q33939254-8182DCB2-7483-4511-A5FC-4DF5FB06B74EQ34202331-D40E3136-8308-4D27-A0CD-2C68F22A44D7Q34762141-5D87B549-B88C-4402-BE35-A252593178D9Q35019915-BBBDAA77-DFAD-422D-837B-0A09DC16DF75Q35084980-13327063-3781-47B4-B492-1B965C7C1F13Q35095045-F7668AFE-CE21-44E4-BA75-5F13D1F19BC7Q35146521-823FD5F4-9151-46E8-9E7C-C054C247398DQ35684819-A73AC6C9-6D05-472B-8466-C3ED3AE5E5CFQ35739010-4D053206-D851-47EF-B27A-01FCB4D89128Q35763497-CDE1D34F-CF12-43BA-AD5D-ED99587C0ADFQ35837803-C6E8F8B8-85EB-41B7-99AD-14D6E3101199Q35940586-CE74669B-D8BE-451A-B5B7-D5DB0255FDF7Q36128774-1E091658-C9F5-4F10-8E8A-4C43892C1F51Q36185559-3604E3F0-C1D3-44D8-9323-4DF9A45B9C07Q36607612-4918E3BB-0E97-48D5-AEEE-5784985CB41FQ36899081-6CE255B3-0275-4A6F-998A-A2B6F837CC16Q36933191-124A8DF0-5620-493F-8ECF-85C914A030EEQ36984703-61243434-6A3A-42CF-AE60-DD3B3BF7A36BQ37272778-AEE43293-3D93-4BED-B80B-01BDEAB080ADQ37385491-6795C54B-9F5E-4A27-82DE-52F9E1E6CAEEQ37457246-609F7CCD-5D2D-4348-820A-AC589A4003EAQ37634515-D01DC1EC-928C-4BB4-BF37-885A1065408EQ37713756-E0437C12-03A9-47A7-9130-75AAEC8A600EQ37727733-6F1B9D93-183D-4B1E-9FF8-A10416A6082BQ37781065-DF0A302C-044C-4FA5-8DEA-E9E1B7DB2CCEQ37782191-F2354E7B-85D1-483B-82B5-C41C01DA96B7Q37929578-1836DF65-B49B-405F-90BD-791BFD283E4CQ38039139-B0DC50A6-B3AF-4661-9922-C73B713D634FQ38065099-08C48FE7-8BA9-4BB5-82A6-C15062AD404BQ38093248-3645C323-06D8-4A91-952A-4B4AAA3D6674
P2860
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Early predictors of mortality ...... -infected patients: 1985-2006.
@en
Early predictors of mortality ...... -infected patients: 1985-2006.
@nl
type
label
Early predictors of mortality ...... -infected patients: 1985-2006.
@en
Early predictors of mortality ...... -infected patients: 1985-2006.
@nl
prefLabel
Early predictors of mortality ...... -infected patients: 1985-2006.
@en
Early predictors of mortality ...... -infected patients: 1985-2006.
@nl
P2093
P2860
P921
P356
P1476
Early predictors of mortality ...... -infected patients: 1985-2006.
@en
P2093
Alison D Grant
Hannah E R Evans
Peter D Walzer
Robert F Miller
Simon G Edwards
P2860
P304
P356
10.1086/526778
P407
P50
P577
2008-02-01T00:00:00Z